Skip to Content
Merck
All Photos(1)

Documents

SFRVN

SAFC

Sf-RVN™ Insect Cell Line

Synonym(s):

Sf9 rhabdovirus-negative (Sf-RVN™) Insect Cell Line

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

description

Sf9 rhabdovirus-negative (Sf-RVN™) Insect Cell Line

solubility

DMSO: 10%

shipped in

liquid nitrogen

storage temp.

−196°C

General description

Sf-RVN(R)cells are provided to customers in vials containing 1 mL at 10 x 106 cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO.
The Sf-RVN™ Insect Cell Line is a rhabdovirus-negative Sf9 cell line that can be grown in both adherent and suspension culture. Sf-RVN™ Insect Cell Line has been adapted for growth in chemically defined medium to be used for the production of recombinant proteins, adeno-associated viruses (AAV) and viral-like particles (VLP). The cell line was tested for adventitious agents and banked under GMP conditions. A technical user guide, with detailed protocols for optimal performances, is provided with the cell line.The EX-CELL® CD Insect Cell Medium, recommended for use, is optimized to get excellent growth and productivity of the Sf-RVN™ Insect Cell Line. Combined, these two products form the Sf-RVN™ Platform.

Cell Line Origin

Sf-RVN™ is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN™ was isolated from Sf9 by GlycoBac, LLC.

Physical form

Sf-RVN™ cells are provided to customers in vials containing 1 mL at 10 x 106cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO

Other Notes

Sf-RVN™ is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN ™ was isolated from Sf9 by GlycoBac, LLC.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
EXACT-AIR is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium

See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.

Bioprocessing And Scale-Up Of Suspension HEK293 Cells For AAV Manufacturing

To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.

High Performance Upstream Platforms for Lentiviral and Adeno-associated Virus Manufacturing

Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and process productivity, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T and Sf9 cells. Draw on our experience today to speed your gene therapy to patients.

Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Related Content

Sf-RVN® Platform

The new Sf-RVN® Platform provides a high performant rhabdovirus-free alternative to produce recombinant proteins, virus-like particles (VLP) for viral vaccines, and adeno-associated viruses (AAV) to treat genetic diseases, improving the safety profile of your gene therapy and vaccines.

Viral Vector Upstream Platforms

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service